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  The report deals with the ！aboratory and clinical assessment of Carbenlciilin （CB－PC） on
urinary tract infection．
  The results obtained were as follows．
  1） The MIC of CB－PC against 268 strains of bacteria isolated from urinary tract infec－
tion were determined by plate dilution method． The MIC were less than 12．5 mcg／dl in 25％
of Staphylococcus aureus， 66，1％ of StaPhylococcus epidermidis， 26．7％ of Enterococcus， 5 ％o of
KlebsielZa， 38．1％ of E． coli， 37．5％ of Proteus vulgaris， 87．5％ of Proteus mirabilis， 66．7％ of
Citrobacter， 14．3％ of Cloaca， 66．7％ of Morganella， 50％ of AZealigenes vulgaris and all of
Providencia， The MIC of Pseudomonas aeruginosa ranged in 25 to 250 rncg／dl．
  As compared with AB－PC， CB－PC was more active against Klebsiella， Proteus vulgaris and
Pseudomonas aerzaginosa and less active against Staphylococcus．
  2） Serum concentration following an intramuscular administration of 1．Ogm in three
healthy adults reached the peak level of 20，8mcg／rn1 in average after 30 rninutes． Urinary
recovery was 49 ％ and cQncentration was 1，227 mcg／ml for 6 hours．
  3） Rat tissue assays were perforrned 30 minutes following an intratnttscular injection of
20mg per kg body weight and the kidney had the highest activity of 51．3mcg／g in average
of three rats， Other tissues were in the following brder， liver， b！ood， lung and spleen．
  ．4） Of． 9 patients with secondary infection by Gram－negative rod afVer surgica！ procgdures，




























Streptococcus aureus hl’ 25 ％，， Streptococcus epi－
dermidisが66．1％， Enterococcusが26．7％， K：1e－
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Table 1Susceptibility of Bacteria isolated from Urinary Tract lnfection





o．210．3gl o．7sl 1．s61 3，13［ 6．2sl 12．sl 2s l so 1100 i 200 1＞200
StaDh． aureus   ム 8 2 1 2 1 2
Staph． epidermidis62 5 1 2 9 10 5 9 5 3 2 6 5
Enterococcus30 2 2 1 2 1 12 2 8
Pseud， aeruginosa23 1 7 13 2
KlebsieUa 42 1 1 1 2 37
E，coli 63 1 1 3 4 15 8 1 3 27
Proteus vulgaris8 1 1 1 2 1 2
Proteus mirabilis8 1 1 2 1 2 玉
Citrobacter 3 2 1
Cloaca 7 ！ 4 1 1
Morganella 3 1 1 1
Providencia 2 2
Alk駐1igenes faecalis．4 1 1 2
Shigella 5 1 1 1 1 ／ 1
epidermidis， Enterococcus， Klebsiella， E． coli，




























（pH 7．2）5m1を順次加え，3，000 rpm IO分間遠心分
離してえられた上清液を試料とした．濃度の測定は薄
層カップ法によった．採取した組織は肝，腎，脾，肺
      桐山・酒徳：Carbenicilli血の検討























o．2 1 o．3gl o．7sl i．s61， 3．i3
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Table 3Blood Levels and Urinary Recoveries （an intramuscular injection of
1．O g in healthy male）
Blood Concentfation（mcg／ml） Urlne（0－6hr．）  お  ㊤   1
   ．R0mm， ！hr．
       1
Qhr．   1 4hr．
































および血清であった．           臨床成績
 その成績はTable 4のごとくであった・すなわち   1）投与対象
抗菌活性は腎でもっとも高く平均51・3tncg／9であっ   対象となった症例は9名で，いずれもグラム陰性桿
た・ついで肝（33・2mcg／9），血清（18・4 mcg／ml），  菌による二次性尿路感染症であった．うち7名は前立
肺（5．Omcg／g），脾（2．Omcg／g）の順であった．   腺摘除術あるいは膀胱憩室切除術後のもので，他の1
        Table 4 Tissue Concentratien （30’rnin． fol／owing an intramuscu／ar injection
              of 20 rng／kg）

































Clinical Evaluation of CB－PC on Secondary lnfection of， Urinary Tract．
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1 M168after prostatectomyProt． mirabilis@      lO6Staph， aur．！02升 冊 一 十 N e貸ective
2 M 7！ after prostatectomyKlebsiella IO8E．coli   lo2冊 冊 ÷ 十 N effective
3 M 65 after prostatectomyE． oli  ！o5E．coli   IO2廿 冊 一 十 N effective
4 M 76 after prostatectomyPseud． aerug．@      lO7Klebsiella 103升 惜 十 十 N effective
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．これを分離菌株で見ると，E， coli 4株， Pseudo－
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